1] Department of International Health, Immunology and Microbiology, Costerton Biofilm Centre Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark. [2] Department of Clinical Microbiology, Rigshospitalet, 2100 Copenhagen Ø, Denmark.
Nat Rev Drug Discov. 2013 Oct;12(10):791-808. doi: 10.1038/nrd4000.
Most of the research on bacterial pathogenesis has focused on acute infections, but much less is known about the pathogenesis of infections caused by bacteria that grow as aggregates in biofilms. These infections tend to be chronic as they resist innate and adaptive immune defence mechanisms as well as antibiotics, and the treatment of biofilm infections presents a considerable unmet clinical need. To date, there are no drugs that specifically target bacteria in biofilms; however, several approaches are in early-stage development. Here, we review current insights into biofilm physiology and pathology, and discuss how a deep insight into the physical and biological characteristics of biofilms can inform therapeutic strategies and molecular targets for the development of anti-biofilm drugs.
大多数关于细菌发病机制的研究都集中在急性感染上，但对于在生物膜中聚集生长的细菌引起的感染的发病机制知之甚少。这些感染往往是慢性的，因为它们会抵抗先天和适应性免疫防御机制以及抗生素，而生物膜感染的治疗存在着相当大的未满足的临床需求。迄今为止，还没有专门针对生物膜中细菌的药物；然而，有几种方法正在早期开发中。在这里，我们综述了目前对生物膜生理学和病理学的认识，并讨论了深入了解生物膜的物理和生物学特性如何为开发抗生物膜药物提供治疗策略和分子靶点。
